TRACY DZIACKY: Open Payments
NPI 1972257558 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,049 in 44 payments from 18 companies in 2025. Trend: 2023 $132 · 2024 $0 · 2025 $1,049
Food & beverage: $1,049
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 11 | $279 |
| Actelion Pharmaceuticals US, Inc. | 4 | $158 |
| Astellas Pharma US Inc | 5 | $153 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $96 |
| Lundbeck LLC | 2 | $37 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 1 | $34 |
| PFIZER INC. | 2 | $33 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
Products named: Wegovy, Veozah, UPTRAVI, CAPLYTA, REXULTI, OPSUMIT, Ozempic, XIFAXAN.
Industry payments across NE — which companies pay providers there.
